World Health Organization

Official UN General Assembly side event: Progress and multisectoral action towards achieving global targets to end TB

On 24 September 2021, the Permanent Mission of the Russian Federation to the United Nations (UN) and the World Health Organization will co-host a special UN General Assembly virtual side event to review progress towards reaching global TB targets, advance multisectoral action and accountability, and discuss preparations for the 2023 UN High-Level Meeting on TB.

Read More →

WHO: Second call for case studies of programmatic innovations

The World Health Organization (WHO) Global TB Program is launching a second call for case studies of programmatic innovations to maintain and improve TB prevention and care in the context of the COVID-19 pandemic.

Read More →

WHO issues rapid communication on updated guidance for the management of TB in children and adolescents

26 August 2021 | Geneva - A rapid communication released by the World Health Organization (WHO) Global Tuberculosis Programme has announced important updates to guidance on the management of tuberculosis (TB) in children and adolescents. This includes new recommendations on diagnostic options, treatment regimens, as well as treatment decision algorithms and optimal models of care for the delivery of child and adolescent TB services.

Read More →

Public call for data on diagnostic accuracy of newer skin-based tests based on specific M. tuberculosis antigens

12 August 2021, Geneva | Currently the most widely used diagnostic tests for TB infection are the tuberculin skin test (TST) and interferon gamma release assays (IGRA). However, both classes of tests have limitations. Newer skin-based tests based on specific M. tuberculosis antigens (ESAT-6, CFP-10 and others) have been developed, these combine the simpler skin-test platform with the specificity of IGRA. Emerging evidence suggests that compared to IGRA, the tests may have similar specificity and provide more reliable results in children and in HIV-infected cohorts. However, the evidence has not been systematically reviewed.

Read More →

Target product profile for next-generation TB drug-susceptibility testing at peripheral sites

10 August 2021 | Geneva - The World Health Organization (WHO) is launching its updated target product profile (TPP) for next-generation drug-susceptibility (DST) testing for M. tuberculosis at peripheral centres.

Read More →

Nigeria records gain in fight against TB amidst coronavirus pandemic

Abuja, 21 July, 2021 - Response to the coronavirus pandemic notwithstanding, data indicate that there has been an increase in annual tuberculosis (TB) case notification due to strategic intervention by  the  National Tuberculosis, Buruli Ulcer and Leprosy Control Program (NTBLCP), in collaboration with World Health Organization (WHO) and other stakeholders working on TB control and elimination in Nigeria.

Read More →

WHO position statement on innovative clinical trial designs for development of new TB treatments

The World Health Organization (WHO) is publishing a position statement on Innovative Clinical Trial Designs for Development of New TB Treatments. This document aims to support TB regimen development by highlighting key clinical trial characteristics to help advance novel therapies. It summarises key innovations in TB clinical trial designs, ranging from pharmacokinetic-pharmacodynamic (PK-PD) modelling and new advances in biomarker development to the value of novel clinical trial design methodologies and post-licensure observational studies.

Read More →

New WHO recommendations issued to improve access to rapid molecular tests for the detection of TB and drug-resistant TB

WHO releases an update to its consolidated guidelines on the detection of TB and drug-resistant TB, accompanied by an operational handbook to facilitate rapid implementation and roll out of rapid molecular tests.

Read More →

Active TB Drug Safety Monitoring and Management (aDSM) global database: Outcome of the assessment and future of data reporting

6 July 2021, Geneva | A global database set up by WHO’s Global Tuberculosis Programme in collaboration with the Special Programme for Research and Training in Tropical Diseases (TDR) has been collating data on Active TB Drug Safety Monitoring and Management (aDSM) since 2016,  to monitor the safety of patients who receive MDR-TB treatment with new medicines (e.g. bedaquiline, delamanid), repurposed medicines (e.g. linezolid, clofazimine) or new regimens, which don't have a well-established safety profile. The aDSM framework has been promoted by WHO and stakeholders since 2015 for monitoring safety for patients who receive MDR-TB treatment with medicines of interest and successfully implemented in many countries for ensuring safety of patients while rolling of the newly recommended MDR-TB treatment regimens.

Read More →

WHO: New invitation for expression of interest to manufacturers of antituberculosis medicines

To support national and global efforts to increase access to and the affordability of TB care and treatment, the World Health Organization (WHO), together with UNICEF, UNAIDS and Unitaid, invites manufacturers of selected pharmaceutical products to submit expressions of interest for product evaluation to the WHO Prequalification Unit.

Read More →

Page 1 of 31 · Total posts: 10

1 2 Last→